Pancreatic cancer: The evolving role of systemic therapy

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 12, 2001, Pages 1939-1947

  El Rayes, B F ^a   Adsay, N V ^a   Philip, P A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Gemcitabine; Pancreatic cancer

Indexed keywords

9 NC; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DEOXYCYTIDINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; ISIS 2503; MITOMYCIN C; MONOCLONAL ANTIBODY; NEW DRUG; NITROSOUREA DERIVATIVE; OXALIPLATIN; PLATINUM DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RUBITECAN; STREPTOZOCIN; TAXANE DERIVATIVE; TIPIFARNIB; TRASTUZAMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BEAM THERAPY; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG INTERACTION; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; FEASIBILITY STUDY; FOOT DISEASE; HUMAN; LEUKOPENIA; MOLECULAR BIOLOGY; MOUSE; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PANCREAS ADENOCARCINOMA; PILOT STUDY; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED STATES;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; HUMANS; PANCREATIC NEOPLASMS;

EID: 0035195144     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.12.1939     Document Type: Review

References (71)

1. Cancer statistics, 2001
2. Cancer of the pancreas
3. Prognostic indicators for survival after resection of pancreatic adenocarcinoma
4. Pancreatic cancer
5. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin, and mitomycin
6. Phase II studies of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil
7. Efficacy of 5FU+cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC): A randomized trial from the French Anticancer Centers Digestive Group (FNLCCDG)
8. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM)
9. Randomized study of 5-FU and CCNU in pancreatic cancer: Report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group
10. 5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer: A Southwest Oncology Group Study
11. Advanced pancreatic cancer: A Phase I-II trial of cisplatin, high-dose cytarabine, and caffeine
12. A Phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma
13. Cisplatin, cytarabine, caffeine and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: A Phase II study
14. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
15. Phase II study of gemcitabine in patients with advanced pancreatic cancer
16. A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
17. Gemcitabine: Effective palliative therapy for pancreatic cancer patients failing 5-FU
18. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
19. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors
20. Randomized Phase II trail of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastic pancreatic adenocarcinoma
21. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer
22. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer
23. Randomized trail of gemcitabine alone or with cisplatin in the treatment of advanced pancreatic cancer: A Phase II multicenter study of the Southern Italy Oncology Group
24. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines
25. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer
26. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A Phase II study
27. First line treatment with docetaxel and gemcitabine in patients with advanced pancreatic cancer
28. Front-line treatment with gemcitabine in combination with Irinotecan: Preliminary results of a multicenter Phase II study
29. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer
30. A Phase II study of rubitecan (9NC) in patients with refractory pancreatic cancer
31. Definitive results of a Phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil and gemcitabine in stage IV pancreatic adenocarcinoma
32. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer
33. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + Gastrointestinal Tumor Study Group
34. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma
35. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone
36. Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracilan Eastern Cooperative Oncology Group study
37. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer
38. Adjuvant therapy of resected adenocarcinoma of the pancreas
39. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil
40. The clinical implications of gemcitabine radiosensitization
41. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
42. A Phase I trial of radiation dose escalation with full dose gemcitabine in patients with pancreatic cancer
43. Clinical evaluation of biologically targeted drugs: Obstacles and opportunities
44. Role of growth factors in pancreatic cancer
45. An insulin-like growth factor-mediated, phosphatidylinositol 3′ kinase- independent survival signaling pathway in beta tumor cells
46. Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target
47. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine
48. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
49. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer
50. Inhibition of ERBB family receptors by CI-1033 enhances the cytotoxicity of gemcitabine via modulation of akt and MAP kinases
51. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells
52. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
53. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
54. Intracellular unesterified arachidonic acid signals apoptosis
55. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
56. COX-2, iNOS and p53 as play-makers of tumor angiogenesis
57. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors
58. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
59. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma
60. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer
61. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
62. Cell cycle-mediated drug resistance: An emerging concept in cancer therapy
63. Novel therapies for pancreatic cancer
64. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase m2 subunit
65. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity
66. Arotinoid mofarotene (RO40-8757) up-regulates p21 and p27 during growth inhibition of pancreatic cancer cell lines
67. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study
68. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma
69. Multicenter Phase II trial of first-line Irinotecan and gemcitabine in patients with locally advanced or metastatic pancreatic cancer (PC)
70. A Phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): An Eastern Cooperative Oncology Group (ECOG) trial
71. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas